Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Gastrointestinal 2Thoracic 1Sarcoma 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Leukemia, Myeloid, Acute 3Hematologic Neoplasms 1

Interventions

Cytarabine 184Cyclophosphamide 176fludarabine 146Azacitidine 121venetoclax 115fludarabine phosphate 104Rituximab 80Decitabine 74Filgrastim 58Specimen Handling 55Etoposide 55Lenalidomide 47Biopsy 45Dexamethasone 41Methotrexate 40Bortezomib 40Mitoxantrone 39Granulocyte Colony-Stimulating Factor 39Daunorubicin 39Vincristine 37Melphalan 36ibrutinib 35Tacrolimus 35Dasatinib 34Whole-Body Irradiation 32Clofarabine 32Peripheral Blood Stem Cell Transplantation 31Mycophenolic Acid 31Injections 31Idarubicin 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × siremadlin × Other hematologic neoplasm × Clear all
NCT05155709 2026-05-07

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Novartis

Phase 1 Completed
14 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03940352 2025-10-10

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Novartis

Phase 1 Terminated
52 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05599932 2025-07-09

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

Novartis

Phase 1 Completed
38 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04496999 2022-10-06

HDMM

Insel Gruppe AG, University Hospital Bern

Phase 1 Terminated
2 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡